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An increased incidence of systemic cancers has been
described in some reports of familial atypical multiple
mole-melanoma kindreds. If the gene defect underlying
the familial atypical multiple mole-melanoma syndrome
is not only important for the development of melanoma
of the skin, the impact of the defect on life expectancy
may be much higher than previously thought. We
investigated all-cause mortality from 1830 to the present
and causes of death from 1941 to 1994 in proven,
obligate, and potential CDKN2 mutation carriers to
obtain an estimate of the impact of a hereditary defect
of the CDKN2 gene on mortality. From 1830 to 1994
there were 65 deaths, although only 42 deaths were
expected [standardized mortality ratio (SMR) 1.6, 95%
confidence interval (CI) 1.2–2.0] and the SMR doubled
Since 1951 there has been mounting evidence that up to12% of cutaneous melanomas cluster in families (Cawley,1952; Greene et al, 1978; Greene and Fraumeni, 1979;Newton, 1994; Haluska and Housman, 1995). In many ofthese families with a susceptibility to melanoma, the indi-
viduals have an underlying syndrome of multiple atypical nevi (Greene
and Fraumeni, 1979; Bergman et al, 1986; Newton, 1994). This
condition, the familial atypical multiple mole-melanoma (FAMMM)
syndrome (Lynch et al, 1978), is also known as the B-K mole syndrome
(Clark et al, 1978), the dysplastic nevus syndrome (Elder et al, 1980),
or the atypical mole syndrome (Newton et al, 1993). The underlying
gene defect has an autosomal dominant inheritance pattern with
variable expression and incomplete penetrance (Bergman et al, 1986),
but it seems plausible that more genes are involved (Newton, 1994).
The three known melanoma susceptibility loci are located on 1p36
(Bale et al, 1989), 12q13 (Zuo et al, 1996), and 9p21 (Kamb et al,
1994). The latter region contains a tumor suppressor gene, the CDKN2
gene, also known as p16INK4. The protein p16 is a cell cycle regulator
and inhibits the kinase activity of CDK4/cyclin D (Serrano et al, 1993).
An increased incidence of systemic cancers has been described in
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with calendar time. Excess mortality was shown in
most of the families, but was confined to ages 35–70 y
(SMR 2.1, 95%CI 1.5–2.9). Excess mortality could be
fully attributed to cancer mortality, especially to
pancreatic carcinoma and melanoma of the skin. There
appeared to be some heterogeneity among the families,
especially due to the specific cancer pattern within a
family. The impact of the defect of the CDKN2 gene
is rising over calendar time, mainly because the
mortality in the general population has been falling.
Excess mortality was not only due to melanoma, but
also to pancreatic carcinoma. Therefore, follow-up
programs of affected family members should not be
confined to a regular check of the atypical nevi. Key
words: causes of death/FAMMM/SMR. J Invest Dermatol
110:788–792, 1998
some reports of FAMMM kindreds (Lynch et al, 1981; Bergman et al,
1990; Tucker et al, 1993); according to others this can be attributed
to the method of ascertainment of the families (Greene et al, 1987).
Neoplasms most often found in those families, besides melanoma of
the skin, are nonmelanoma skin cancer and cancers of the lung,
breast, stomach, pancreas, large bowel, and endometrium (Greene and
Fraumeni, 1979). If the gene defect underlying the FAMMM syndrome
is not only important for the development of melanoma of the skin,
but also for a whole range of other life threatening systemic neoplasms,
the impact of the defect on life expectancy may be much higher than
previously thought. Knowledge of the natural history of the effects of
mutations in the CDKN2 gene may have consequences for follow-up
programs of affected family members.
Life expectancy in individuals with the FAMMM syndrome can
only be studied during long-term follow-up. We developed a method
to study the survival of family members retrospectively by extending
the follow-up to the past (Rosendaal et al, 1991). In this study we
selected six FAMMM pedigrees and investigated all-cause mortality
from 1830 to the present and causes of death from 1941 to 1994 in
proven, obligate, and potential carriers to obtain an estimate of the
impact of a hereditary defect of the CDKN2 gene on mortality and
causes of death.
MATERIALS AND METHODS
Study population In February 1982 the Pigmented Lesions Clinic of the
Department of Dermatology was established, facilitating studies on familial
melanoma. From this database, 10 families were found with more than two
melanoma patients in at least two consecutive generations and in which several
family members showed atypical nevi. These FAMMM families have been
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described in detail elsewhere (Bergman et al, 1986, 1990, 1992; Vasen et al,
1989). Six families, all showing an autosomal dominant pattern of inheritance
for a 19 bp deletion in exon 2 of the CDKN2 gene, were included in our
current investigation (Gruis et al, 1995). Two of the four remaining families
had the deletion but were not suitable for the mortality analysis because of an
unclear inheritance pattern of the CDKN2 gene, and two families originated
from a different part of the Netherlands and did not show the deletion.
We restricted the study population to proven carriers of the deletion in
CDKN2, obligate, and potential gene carriers. Proven CDKN2 deletion carriers
had been confirmed by DNA analysis to carry the mutation (Gruis et al, 1995).
Obligate carriers were family members who had passed on the gene from
common ancestors to gene carriers amongst their offspring. Potential carriers
were defined as all first degree relatives of gene carriers. Some of the potential
carriers could be tested for the deletion; however, the outcome on the DNA
test was only used to enlarge the pedigrees, meaning that all potential carriers
were part of the study population regardless of their DNA test. (Because only
living family members could undergo the test, excluding potential carriers after
the test would introduce bias towards deceased people.)
Using church and municipal registers of births, marriages, and deaths, we
retrieved the dates of birth and death for all individuals. Because the obligate
carriers had to live until the birth of the proven carrier to pass on the mutation,
the person-years lived before 20 y of age were ignored in these carriers. Besides,
because only a few melanoma occur before 20 y of age, the best estimate of
the gene impact on life expectancy can be made from this age on. Therefore,
follow-up extended from 20 y after the date of birth to the date of death or to
December 31, 1994.
Causes of death We were able to survey all causes of death of persons who
died in the Netherlands between 1941 and 1994. These were made available
by the Netherlands Central Bureau of Statistics, where one copy of each death
certificate is kept. The causes of death are routinely coded by this Bureau using
the coding rules from the International Classification of Diseases, fifth through
ninth revision (ICD-5 through ICD-9; WHO, 1940, 1948, 1957, 1968, 1977).
For the analysis, the older ICD codes were recoded to conform to the ninth
revision. We classified the deceased persons into malignant neoplasms (ICD-9
codes 140.0–209.9), diseases of the circulatory system (ICD-9 codes 390.0–
459.9), and remaining causes of death. Malignant neoplasms were further
divided into cancers of the digestive organs other than pancreas (ICD-9 codes
150.0–159.9, excluding 157), pancreatic carcinoma (ICD-9 codes 157.0–157.9),
melanoma of the skin (ICD-9 codes 172.0–172.9), and remaining cancers. The
comparison of causes of death was based on death certificate classifications to
guarantee a valid comparison as the classification was the same for both the
study and the control populations.
Statistical analysis Mortality data were analyzed with the Family Tree
Mortality Ratio method (Rosendaal et al, 1991; Hille et al, 1997): the overall
and cause-specific mortality of the FAMMM families (observed) was compared
with that of the general Dutch population adjusted for sex, age, and calendar
period (expected). The ratio of observed to expected number of deaths is the
standardized mortality ratio (SMR), which can be viewed as a relative risk.
The expected mortality was derived by multiplying the total number of years
lived by the study population per category of sex, age, and calendar period
with the corresponding cause-specific population mortality rates obtained from
the annual reports of the Netherlands Central Bureau of Statistics, using the
computer program ‘‘Person-years’’ (Coleman et al, 1986). The 95% confidence
interval (95%CI) for the SMR is based on a Poisson distribution for the
observed number of deaths (Breslow and Day, 1987).
The calendar periods were divided into 20 y intervals from 1830 to 1889, a
15 y interval from 1890 to 1904, and 10 y intervals from 1905 to 1994. To
each of these periods we applied the population mortality rates of the mid-
interval year, subdivided by sex and into 5 y age groups. For the causes of
death the calendar periods were assigned to 5 y intervals from 1941 to 1994,
subdivided by sex and into 5 y age classes. To each of these periods we applied
the cause-specific population mortality rates of the mid-interval year, starting
from the mid-interval year 1943 (period 1941–45) and running until 1993
(period 1991–94).
Finally, to study differences among the families, we extended the SMR
analysis with Poisson regression analysis, using ‘‘EGRET’’ (EGRET, 1992).
This multivariate analysis calculated rate ratios for the different families adjusted
for sex, age, and calendar periods. We determined the differences between the
families for all-cause mortality and for mortality from malignant neoplasms from
1941 to 1994. The pedigree that contributed most of the individuals and
person-years to the analysis was taken as the reference category.
RESULTS
Characteristics of the study population Table I gives an overview
of the characteristics of the study population for the six families. From
1830 to 1994, 224 family members, who were at least 20 y of age,
were followed over 6022 person-years. There were 87 proven, 23
obligate, and 114 potential CDKN2 gene carriers. Birth year ranged
from 1829 to 1974 and year of death from 1874 to 1994. The mean
age at the end-of-study date was 40.9 y (SD 15.4). For the entire study
population the mean age at death was 61.5 y (SD 16.7). In the 126
men the mean age at death was 59.1 y (SD 17.0), whereas the 98
women had a mean age at death of 65.3 y (SD 15.8).
All-cause mortality Over the whole period 65 deaths occurred,
whereas only 42 deaths were expected (SMR 1.6, 95%CI 1.2–2.0). In
men, 40 individuals died in 3497 person-years, leading to a SMR of
1.5 (95%CI 1.1–2.0), and 25 women died in 2525 person-years (SMR
1.6, 95%CI 1.1–2.4). Excess mortality was shown in most of the
families, although there was some heterogeneity between the families
(Fig 1). The SMR doubled with calendar time, from 1870 to the
present (Fig 2). From the calendar period 1925–44 onward, the SMR
differed from unity, but the increase was only significant from 1975
onwards. Furthermore, Fig 3 shows that excess mortality was confined
to the ages 35–70 y (SMR 42/19.7 5 2.1, 95%CI 1.5–2.9), with the
mortality peak between 40 and 50 (SMR 15/3.8 5 4.0, 95%CI 2.2–6.6).
Causes of death For the analysis of the causes of death between
1941 and 1994, 59 death certificates were reviewed. The all-cause
SMR over this period was slightly higher than for the whole period,
as a result of a higher SMR in women (Table II). Excess mortality
can fully be attributed to malignancies, especially to melanoma of the
skin and pancreatic carcinoma, although half of the malignant neoplasms
resulted from several tumors, such as lung, breast, and stomach cancers
(Table II). Separating the study population into proven and obligate
CDKN2 gene carriers versus potential carriers led to very similar
patterns in both groups, with, as expected, the most pronounced risks
for those who were carriers with certainty (Table III). Because these
families have been ascertained on the basis of a history of melanoma,
there may be some bias in the melanoma mortality. The unbiased
result would be mortality other than melanoma of the skin. In these
families there were 49 deaths for reasons other than melanoma, leading
to a SMR of 1.4 (95%CI 1.1–1.9), and there were 34 deaths from
malignant neoplasms other than melanoma, with a SMR of 3.6 (95%CI
2.5–5.1).
Table IV shows all-cause mortality and deaths from malignant
neoplasms for the different families compared with the general Dutch
population (SMR) and compared with pedigree 10 (Poisson rate ratio;
the largest family). None of the differences between the families were
significant. Furthermore, it was striking that in two kindreds (FAMMM
1 and 5) no one died from pancreatic cancer, and that in pedigree
number 5 no deaths from melanoma of the skin were mentioned on
the death certificates (Table IV).
DISCUSSION
We studied the mortality patterns in six FAMMM pedigrees. The all-
cause lifetime SMR for proven, obligate, and potential carriers with a
deletion in the CDKN2 gene was 1.6, with no significant differences
between men and women. Excess mortality started after the age of
30 y and could be fully attributed to cancer mortality. We found a
secular increase of mortality in the FAMMM families, mainly because
of decreasing mortality rates in the Dutch population over the past
century. From the calendar period 1925–44 onward, the SMR differed
from unity, but the increase was only significant from 1975 onwards.
This means that the impact of the 19 bp deletion in exon 2 of the
CDKN2 gene is rising; in comparison with the general population it
becomes more disadvantageous to carry this gene.
All the FAMMM families were detected from the Pigmented Lesions
Clinic as six separate families; however, when we found out that these
families all had the same 19 bp deletion in exon 2 of the CDKN2
gene, we started looking for common ancestors, especially because all
pedigrees came from the region of Leiden. From the finding of shared
haplotype among the melanoma patients, it had already been suggested
that there was a common mutation in the pedigrees (Bergman et al,
1994; Gruis et al, 1995). Genealogic investigation could confirm this
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Table I. Characteristics of the study population, ù 20 y of age
FAMMM Number (Obligate) Potential Mean age at Number of Person-
family carriers a carriers death (SD) deaths years
1 25 12 13 61.7 (14.8) 9 646
3 40 15 25 69.5 (17.0) 18 1418
4 52 35 17 58.4 (17.5) 16 1316
5 20 9 11 50.1 (13.6) 4 437
10 56 24 32 58.9 (17.4) 12 1439
19 31 15 16 58.6 (12.1) 6 766
224 110 114 61.5 (16.7) 65 6022
aProven and obligate carriers.
Figure 1. Excess mortality is present in most families. SMR with 95%CI,
per FAMMM family from 1850 till 1994, ù 20 y of age.
Figure 2. The SMR is rising over calendar time. SMR with 95% CI, in
FAMMM families according to calendar periods, ù 20 y of age.
Figure 3. Excess mortality is confined to age groups 40–70 y. SMR with
95%CI, in FAMMM families according to age groups from 1850 till 1994.
assumption: families 1 and 4 have common ancestors in 1775, and
together with kindred 3, they have a common ancestor in 1707.
Pedigrees 10 and 19 have common ancestors in 1763. We expect all
these FAMMM families to have one founder (far) before 1700. This
means that the differences between the families can be seen as differences
between branches of one pedigree. As a consequence of new incoming
genes through spouses, differences between the different branches
develop.
There appears to be some heterogeneity among the families, especially
when taking into account the specific cancer pattern within a family.
In FAMMM families 1 and 5, there were no deaths from pancreatic
carcinomas and in kindred 5 no deaths from melanoma of the skin
were mentioned. This could be due to the small numbers studied.
Compared with family 10, all other kindreds had higher mortality
rates, though not significant. Families 1 and 4 were expected to be
more equal than the other families, because of the nearness of their
common ancestor. For the all-cause mortality and total cancer mortality
estimates this seemed to hold, although the specific cancer patterns in
these families differed.
Half of the cancer deaths were due to melanoma (10 deaths) and
pancreatic neoplasms (12 deaths). In addition, we also found an
increased mortality from digestive carcinomas other than pancreatic
(four deaths from stomach cancer), and from remaining cancers such
as lung (five deaths) and breast (three deaths) cancers. All these types
of neoplasms had already been described in previous reports of FAMMM
kindreds, and relative risk estimates for melanoma and pancreatic
carcinoma were similar (Greene and Fraumeni, 1979; Lynch et al,
1981; Bergman et al, 1990; Tucker et al, 1993). These results confirm
the recent findings from Whelan et al (1995) that CDKN2 plays an
important role in both melanoma and pancreatic tumorgenesis. In the
same issue, Goldstein et al (1995) concluded that for the occurrence
of pancreatic cancer in FAMMM families, a mutation in the CDKN2
gene is required and that differences in cancer patterns between families
might be explained by the kind of mutation; however, from the Dutch
families it has already been suggested that the differences in cancer
patterns cannot exclusively be explained by the kind of CDKN2
mutation, but have to be influenced by other environmental or genetic
factors (Bergman and Gruis, 1996). The impression that it is really the
CDKN2 gene that is causing the pancreatic carcinoma, is reinforced
as the mortality risk was stronger in proven and obligate gene carriers
than in potential gene carriers. In both groups excess mortality could
be fully attributed to cancer mortality, especially to pancreatic carcinoma
and melanoma of the skin. Further evidence was given by the study
of Gruis et al (1995), where loss of heterozygosity of CDKN2 was
shown in pancreatic carcinoma tissue of one of the family members.
These FAMMM pedigrees have been ascertained on having more
than two melanoma patients in at least two consecutive generations
from the Pigmented Lesions Clinic. Therefore, the results could be
biased for deaths from melanoma. When omitting the melanoma
mortality, the excess mortality remained, meaning that deaths from
other cancers were as important as the melanoma mortality. This is
slightly different from the morbidity figures, where melanoma incidence
seems the most pronounced. Follow-up programs for the CDKN2
mutation carriers in these FAMMM kindreds, at this moment, consist
of a yearly check of the atypical nevi; however, on the basis of our
results the question is whether these gene carriers should not be
screened for cancers other than melanoma, especially for pancreatic
carcinoma. The problem is that currently no appropriate intervention
programs are available. From that perspective, it might be worthwhile
to study whether screening on serum tumor markers, like CA19–9 or
CA494 (Safi et al, 1986; Pleskow et al, 1989; Friess et al, 1993; Audisio
et al, 1996; Gansauge et al, 1996), in combination with regular
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Table II. Observed and expected number of deaths for the different causes of death between 1941 and 1994, ù 20 y of age
Condition Gender Oa Eb SMR 95%CI
All-cause mortality All 59 34.6 1.7 1.3–2.2
Men 35 22.6 1.6 1.1–2.2
Women 24 12.0 2.0 1.3–3.0
Malignant neoplasms All 44 9.4 4.7 3.4–6.3
Men 26 6.1 4.3 2.8–6.2
Women 18 3.3 5.5 3.2–8.6
Digestive cancer,c All 7 2.7 2.6 1.1–5.4
excluding pancreas Men 3 1.6 1.8 .38–5.3
Women 4 1.0 3.9 1.1–9.9
Pancreatic carcinoma All 12 0.38 31.4 16–55
Men 7 0.25 28.0 11–58
Women 5 0.13 37.6 12–90
Melanoma of skin All 10 0.09 110 53–204
Men 5 0.06 87 27–194
Women 5 0.03 148 54–389
Remaining cancersd All 15 6.2 2.4 1.4–4.0
Men 11 4.1 2.7 1.3–4.8
Women 4 2.1 1.9 0.52–4.9
Circulatory diseases All 8 13.9 0.57 0.25–1.1
Men 5 9.2 0.54 0.18–1.3
Women 3 4.8 0.63 0.13–1.8
Remaining causes of death All 7 11.3 0.62 0.25–1.3
Men 4 7.3 0.55 0.15–1.4
Women 3 3.9 0.76 0.16–2.2
aObserved number of deaths.
bExpected number of deaths.
cFour stomach, two biliary ducts, one colon.
dFive lung, three breast, two brain, one salivary gland, one nasopharynx, one prostate, one abdomen, one disseminated.
Table III. Similar mortality pattern for potential carriers, though diluted, as for proven and obligate carriers
(Obligate) carriers Potential carriers
Condition Observed SMR Observed SMR
All-cause mortality 29 2.9 30 1.2
Malignant neoplasms 25 8.7 19 2.9
Digestive cancer, excluding pancreas 4 5.0 3 1.6
Pancreatic carcinoma 7 63.6 5 17.8
Melanoma of skin 6 150 4 66.7
Remaining cancers 8 4.2 7 1.6
Circulatory diseases 2 0.6 6 0.6
Remaining causes of death 2 0.6 5 0.6
Table IV. All-cause mortality and deaths from malignant neoplasms for the different families compared with the general Dutch
population (SMR) and compared with each other (Poisson rate ratio), between 1941 and 1994, ù 20 y of age
All-cause mortality Malignant neoplasms
FAMMM
family Oa SMRb PRRc Oa SMRb PRRc Digd Pane Melf Remg
1 8 2.2 [0.9–4.3] 2.1 [0.7–5.9] 6 5.4 [2.0–12] 2.8 [0.8–9.5] 2 0 2 2
3 18 1.2 [0.7–1.9] 1.3 [0.5–3.1] 14 3.9 [2.1–6.5] 2.0 [0.7–5.8] 3 4 2 5
4 16 2.4 [1.4–3.9] 1.9 [0.8–4.6] 11 6.0 [3.0–11] 2.2 [0.8–6.5] 0 4 2 5
5 3 2.5 [0.5–7.3] 1.6 [0.4–5.9] 2 4.9 [0.6–18] 1.5 [0.3–7.8] 0 0 0 2
10 8 1.5 [0.6–2.9] 1 5 3.2 [1.0–7.5] 1 1 2 2 0
19 6 2.2 [0.8–4.8] 1.5 [0.5–4.4] 6 6.7 [2.5–15] 2.3 [0.7–7.6] 1 2 2 1
aObserved number of deaths.
bStandardized mortality ratio with 95%CI in brackets.
cPoisson rate ratio with the largest family (family 10) as the reference group and 95%CI in brackets.
dObserved number of deaths from digestive cancer, excluding pancreas.
eObserved number of deaths from pancreatic carcinoma.
fObserved number of deaths from melanoma of skin.
gObserved number of deaths from remaining cancers.
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endoscopic ultrasonography or magnetic resonance imaging, for pancre-
atic carcinoma in CDKN2 mutation carriers, might prevent more early
mortality in FAMMM families.
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